Merck & Co., US58933Y1055

Merck stock gets EU backing for ENFLONSIA expansion

Published on 11/17/2026 at 13:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Merck & Co. stock is in focus after a positive EU recommendation for ENFLONSIA in vulnerable children up to 24 months. The Commission will decide next.

ENFLONSIA Expansion Awaits EU Decision

  • Merck said the EU medicines committee recommended extending ENFLONSIA prevention to vulnerable children through their second RSV season.
  • The European Commission is expected to decide on the recommendation within two months.
  • The FDA set March 22, 2027, as the target action date for Merck's corresponding US application.
Merck & Co., US58933Y1055, Illustration mit AI erstellt.

On November 13, Merck said the European Medicines Agency's Committee for Medicinal Products for Human Use had adopted a positive opinion recommending an expanded indication for Merck's ENFLONSIA. The recommendation would extend prevention of respiratory syncytial virus lower respiratory tract disease to children up to 24 months of age who remain at increased risk through their second RSV season.

Regulatory Step Comes Before EU Approval

The CHMP recommendation now goes to the European Commission for marketing authorization in the European Union, Iceland, Liechtenstein and Norway. Merck said a final decision is expected within two months, so the regulatory process remains incomplete.

ENFLONSIA is already approved in the United States and European Union for infants born during or entering their first RSV season. Merck said the product is administered without weight-based dosing and is approved in more than 55 countries worldwide.

The company linked the recommendation to the Phase 3 SMART trial, which studied infants and children at increased risk of severe RSV disease over two RSV seasons. The trial included children with chronic lung disease, congenital heart disease and certain early or moderately preterm births. In the second season, eligible participants received an additional 210 mg dose of ENFLONSIA.

US Decision Has A Separate Timeline

Merck said the US Food and Drug Administration accepted a supplemental biologics license application covering children under two at increased risk through their second RSV season. The agency set March 22, 2027, as the target action date.

Merck & Co. stock traded at 130.81 euros on Lang & Schwarz at 13:19 CET on Tuesday, November 17, 2026.

Merck & Co. stock details

  • Company: Merck & Co., Inc.
  • ISIN: US58933Y1055
  • Lang & Schwarz quote: 130.81 euros on November 17, 2026, at 13:19 CET

US pharmaceutical shares traded against the backdrop of the S&P 500 market environment.

More news and analyses on Merck & Co. stock

Disclaimer...
en | US58933Y1055 | MERCK & CO. | boerse | 70526751 | bgmi